OBJECTIVE:To investigate the inhibitory effect of astragalus polysaccharide(APS)on the proliferation of human neuroblastoma SH-SY5Y cells. METHODS:After the cells were cultured with 0(blank control),25,50 and 100 mg/ml APS for 6,12 and 24 h,MTT method was used to determine cell viability and calculate inhibition rate. Following cell cultured with 0 (blank control),25,50 and 100 mg/ml APS for 24 h,Hoechst 33258 fluorescent staining was performed,and then cell nucleus morphology was observed under the fluorescence microscope;flow cytometer was used to detect the distribution of cell cycles and apoptosis;western blot was employed to determine the expression of extracellular regulated protein kinases (ERK) 1/2 protein in cells. Enzyme linked immunosorbent assay (ELISA) was conducted to determine the contents of interleukin 2 (IL-2),IL-6 and IL-12 in the cells. RESULTS:Compared to the blank control,those cultured with 100 mg/ml APS for 6 h,50 and 100 mg/ml APS for 12 h and 25,50 and 100 mg/ml APS for 24 h demonstrated higher inhibition rate. After the cells were cultured with 50 and 100 mg/ml APS for 24 h,those in G0/G1 phase increased and those in G2/M and S phases decreased,and the contents of IL-2 and IL-6 increased. After cells were cultured with 25,50 and 100 mg/ml APS for 24 h,the apoptosis rate was higher,densely hyperchromat-ic fragments in cell nuclei and apoptotic bodies appeared,the phosphorylation level of ERK1/2 protein in the cells was lower,and the content of IL-12 was higher. There was statistically significance (P<0.01 or P<0.05). CONCLUSIONS:APS can inhibit the proliferation of SH-SY5Y cells by arresting cell cycle and inducing cell apoptosis through a mechanism which may be correlated to the decrease in the phosphorylation of ERK1/2 and increase in cytokine.

Objective:To investigate the role of Smad7 in the Hepatocellular carcinoma (HCC) migration and proliferation and its clinical significance.Methods:Through transfecting pcDNA3.1 (+)-Smad7 or siRNA Smad7 to overexpress or knockdown the Smad7 expression in HCC cell lines HepG2 and Huh7.The MTT assays were used to test the role of Smad7 in proliferation of HCC cells.Transwell and wound-healing assays were used to detect the effect of Smad7 on migratory ability in both tow cell lines.RT-PCR was used to test the Smad7 expression in 9 clinical HCC patients' specimens.Results:As the results,overexpression of Smad7 significantly inhibited the proliferation of cells compared with the control group,while knockdown Smad7 promoted the proliferation.At the same time,overexpression of Smad7 could inhibit the migratory ability of HCC cells compared with the control group,while knockdown smad7 could accelerate this ability.The expression of Smad7 in cancer tissue was significantly lower compared with normal mucosa tissue adjacent to cancer.Conclusions:Smad7 is a kind of anti-progressive molecule in HCC.

Objective To compare the efficacy and safety of linezolid and vancomycin in the treatment of hospitalized patients with Enterococcus bloodstream infection,to provide medication choices for clinical practice.Methods The clinical data of 99 inpatients with Enterococcus bloodstream infection in Yantai Yuhuangding Hospital from June 2019 to June 2023 were retrospectively collected,and the patients were divided into linezolid group and vancomycin group according to the drug used.confounding factors were controlled by propensity score matching method.The clinical efficacy,inflammatory factor levels,and adverse reactions of the two groups were compared.Results After using propensity score matching,25 patients were assigned to both linezolid group and vancomycin group.There was no significant difference in the effective rate,30-day mortality,incidence of adverse reactions and inflammatory factor levels between the two groups(P＞0.05).Conclusion In the treatment of patients with Enterococcus bloodstream infection,the efficacy and safety of linezolid and vancomycin are the same.Linezolid can be a prioritized medicine when vancomycin causes nephrotoxicity and concentration does not meet the standard or exceeds the standard.Due to limitation of sample size and information collection,more high-quality studies are required to verify above conclusions.

Objective:To analyze the etiological characteristics of epidemic cerebrospinal meningitis caused by serogroup Y Neisseria meningitidis ( Nm) in Fujian Province. Methods:The strain identification, serogroup identification, antimicrobial susceptibility test, molecular typing, average nucleotide identity (ANI), core genome multilocus sequence typing (cgMLST), and single nucleotide polymorphism (SNP) analysis were performed on eight Nm strains isolated from cases of epidemic cerebrospinal meningitis, close contacts, or healthy population. Results:All eight isolates from Fujian Province in 2024 were serogroup Y Nm strains. The antimicrobial susceptibility test for 12 antibiotics showed that all isolates from Fujian Province in 2024 were resistant to trimethoprim-sulfamethoxazole, and NMFJ202406 and NMFJ202407 isolates were resistant to nalidixic acid and intermediate to ciprofloxacin, while the others were sensitive to antibiotics such as penicillin, cefotaxime, and ceftriaxone. All isolates were ST-1655 sequence type (ST), except for NMFJ202406 isolate which were ST-2039, and all isolates belonged to clonal complex 23 (CC23). The finetyping antigen profile of all isolates were P1.5-1, 10-1: F4-1. ANI and phylogenetic analysis indicated that the isolates in Fujian Province were mainly divided into two clusters, namely NMFJ202401 and its close contact isolates (NMFJ202402-NMFJ202405), as well as NMFJ202406, NMFJ202407, and NMFJ202408 isolates. Compared to the isolates from Guangdong, Shanghai, and Hebei Provinces, the strains isolated in Fujian Province were more closely related to the strains isolated in Canada (NML2019-167, 2019), Japan (NIID501, 2009), and the United Kingdom (CA41956, 2015), respectively. Conclusions:This is the first report of epidemic cerebrospinal meningitis caused by serogroup Y Nm isolates in Fujian Province, which might be transmitted from different sources abroad and have spread in many areas. In the future, the wider usage of tetravalent meningococcal vaccine ACYW135 is needed, and the epidemiological and etiological surveillance of serogroup Y epidemic cerebrospinal meningitis should be strengthened.